| Subject: | FDA Issues Notice on Changes to Ontak Labeling |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Thu, 23 Mar 2006 - 10:00 am |
| Audience: Hemato-oncological healthcare professionals
Ligand Pharmaceuticals and the FDA have notified healthcare professionals of changes to the WARNINGS section of the prescribing information for Ontak (denileukin diftitox), indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma.
Loss of visual acuity usually with loss of color vision with or without retinal pigment mottling has been reported following administration of Ontak. While recovery was... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert! provides immediate notification of regulatory body legislation impacting the healthcare industry, helping you to meet regulatory compliance. Subscribers are notified of any new or revised regulations, provided with a summary of the regulation, followed by an implementation action plan and/or policy. Designed as an e-mail "push" method for rapid customer notification of healthcare compliance issues, paired with interpretative analysis and practical application, the StayAlert!® Virtual Compliance Administrator™ saves you time and money. Currently StayAlert! is the leader in the comprehensive compliance information marketplace. Why? Because StayAlert! provides healthcare professionals with more than information. StayAlert! provides a service, in many cases "doing the work" for you, and assisting regulatory compliance officers to effectively and efficiently meet changing standards. |
|
